NCT07151521 (68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
| NCT ID | NCT07151521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | ANCA-associated Vasculitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2025-09-01 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pulmonary and renal involvement are the most common clinical manifestations of antineutrophil cytoplasmic antibody(ANCA)-associated vasculitis (AAV). Studies have shown that both interstitial lung disease (ILD) and renal dysfunction are closely associated with poor prognosis in patients with AAV. Therefore, early identification of whether AAV patients have concomitant ILD and renal involvement is of great clinical importance for assessing disease severity, stratifying prognostic risk, and developing individualized treatment strategies. Positron emission tomography (PET) is a noninvasive molecular imaging technique that can provide decision-making support for early and accurate diagnosis, timely intervention, as well as evaluation of treatment response and prognosis. In the same individual, PET enables whole-body localization of disease in a single examination, overcoming the limitation of conventional diagnostic methods that typically assess only one region at a time, thereby facilitating patient benefit. In recent years, many novel PET tracers have been developed and introduced into clinical practice. 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) has been studied in the diagnosis of various malignant and nonmalignant diseases; it targets fibroblast activation protein (FAP) and thus reflects the distribution of cancer-associated fibroblasts (CAFs). However, its clinical significance in AAV remains to be further investigated. This study aims to use a CAF-targeted novel PET tracer to conveniently and noninvasively detect the real-time distribution of lesions in patients, providing valuable information for personalized diagnosis and treatment.
Eligibility Criteria
Inclusion Criteria: 1. Age over 18 years; 2. Meeting the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for ANCA-associated vasculitis; 3. Diagnosed with concomitant interstitial lung disease based on High-Resolution Computed Tomography (HRCT) images obtained within one year prior to enrollment, interpreted by two radiologists blinded to clinical information; 4. Complete clinical information available; 5. Signed and dated informed consent form; 6. Willingness to comply with the study procedures and cooperate throughout the entire study process. Exclusion Criteria: 1. Presence of other rheumatic diseases; 2. Presence of other conditions that may cause interstitial lung disease or renal impairment, such as systemic lupus erythematosus, dermatomyositis, or rheumatoid arthritis; 3. History of, or planned, hematopoietic stem cell transplantation; 4. Presence of severe comorbidities deemed by the investigators to be unsuitable for participation in this clinical study, such as severe cardiopulmonary insufficiency, severe bone marrow suppression, or severe hepatic or renal insufficiency; 5. Acute abdominal emergencies such as intestinal perforation or complete intestinal obstruction; 6. Pregnant or potentially pregnant women, and lactating women; 7. Poor treatment compliance.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07151521 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ANCA-associated Vasculitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07151521 currently recruiting?
Yes, NCT07151521 is actively recruiting participants. Contact the research team at hong-lei-liu@163.com for enrollment information.
Where is the NCT07151521 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07151521 clinical trial?
NCT07151521 is sponsored by Ruijin Hospital. The trial plans to enroll 30 participants.